Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Transplantation | 18 | 2020 | 517 | 1.940 |
Why?
|
Tissue Donors | 11 | 2018 | 198 | 1.330 |
Why?
|
Delayed Graft Function | 4 | 2018 | 33 | 0.760 |
Why?
|
Graft Survival | 13 | 2019 | 314 | 0.710 |
Why?
|
Living Donors | 3 | 2020 | 64 | 0.620 |
Why?
|
Donor Selection | 5 | 2020 | 33 | 0.550 |
Why?
|
Kidney Failure, Chronic | 4 | 2016 | 541 | 0.540 |
Why?
|
Health Services Accessibility | 2 | 2017 | 242 | 0.500 |
Why?
|
Insurance Coverage | 1 | 2013 | 75 | 0.420 |
Why?
|
Tissue and Organ Procurement | 6 | 2018 | 93 | 0.420 |
Why?
|
Acetanilides | 1 | 2010 | 5 | 0.370 |
Why?
|
Ethnic Groups | 1 | 2013 | 476 | 0.360 |
Why?
|
Piperazines | 1 | 2010 | 54 | 0.360 |
Why?
|
Tacrolimus | 1 | 2010 | 65 | 0.360 |
Why?
|
Complement C1q | 1 | 2010 | 4 | 0.360 |
Why?
|
Enzyme Inhibitors | 1 | 2010 | 165 | 0.350 |
Why?
|
Glomerulosclerosis, Focal Segmental | 1 | 2010 | 38 | 0.350 |
Why?
|
Molecular Motor Proteins | 1 | 2010 | 58 | 0.340 |
Why?
|
Myosin Heavy Chains | 1 | 2010 | 89 | 0.340 |
Why?
|
Apolipoproteins | 4 | 2016 | 200 | 0.320 |
Why?
|
Immunosuppressive Agents | 1 | 2010 | 240 | 0.320 |
Why?
|
Diabetic Neuropathies | 1 | 2008 | 24 | 0.320 |
Why?
|
Lipoproteins, HDL | 4 | 2016 | 251 | 0.320 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2008 | 21 | 0.320 |
Why?
|
Amines | 1 | 2008 | 22 | 0.320 |
Why?
|
Hearing Loss | 1 | 2008 | 26 | 0.320 |
Why?
|
Anticonvulsants | 1 | 2008 | 65 | 0.310 |
Why?
|
Follow-Up Studies | 8 | 2019 | 2280 | 0.310 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2008 | 75 | 0.310 |
Why?
|
Pancreas Transplantation | 3 | 2014 | 247 | 0.260 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2020 | 288 | 0.250 |
Why?
|
Female | 17 | 2019 | 19953 | 0.250 |
Why?
|
Graft Rejection | 3 | 2018 | 238 | 0.250 |
Why?
|
African Americans | 4 | 2017 | 1428 | 0.240 |
Why?
|
Caveolin 1 | 2 | 2015 | 13 | 0.240 |
Why?
|
Survival Rate | 6 | 2018 | 885 | 0.240 |
Why?
|
Middle Aged | 15 | 2019 | 11868 | 0.230 |
Why?
|
Retrospective Studies | 10 | 2019 | 3523 | 0.230 |
Why?
|
Humans | 22 | 2020 | 32024 | 0.220 |
Why?
|
Genetic Testing | 2 | 2020 | 96 | 0.200 |
Why?
|
Male | 15 | 2019 | 19195 | 0.200 |
Why?
|
Adult | 14 | 2019 | 9366 | 0.190 |
Why?
|
Kidney Diseases | 2 | 2014 | 249 | 0.180 |
Why?
|
Prognosis | 5 | 2018 | 1505 | 0.180 |
Why?
|
Cadaver | 6 | 2018 | 161 | 0.160 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 1067 | 0.160 |
Why?
|
Cold Ischemia | 1 | 2018 | 7 | 0.150 |
Why?
|
Time Factors | 4 | 2016 | 2152 | 0.150 |
Why?
|
C-Peptide | 2 | 2014 | 29 | 0.150 |
Why?
|
Postoperative Complications | 2 | 2020 | 785 | 0.130 |
Why?
|
African Continental Ancestry Group | 2 | 2020 | 363 | 0.130 |
Why?
|
United States | 4 | 2017 | 3938 | 0.130 |
Why?
|
Aged | 7 | 2019 | 10340 | 0.130 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 835 | 0.120 |
Why?
|
Tissue and Organ Harvesting | 2 | 2020 | 35 | 0.120 |
Why?
|
Glomerular Filtration Rate | 4 | 2018 | 305 | 0.120 |
Why?
|
Haplotypes | 2 | 2015 | 220 | 0.120 |
Why?
|
Incidence | 1 | 2016 | 1200 | 0.110 |
Why?
|
Risk Factors | 6 | 2018 | 3869 | 0.110 |
Why?
|
Disease Progression | 2 | 2014 | 594 | 0.100 |
Why?
|
Kidney Function Tests | 3 | 2018 | 106 | 0.100 |
Why?
|
Aged, 80 and over | 2 | 2017 | 4000 | 0.100 |
Why?
|
Young Adult | 5 | 2019 | 2615 | 0.100 |
Why?
|
Diabetes Mellitus | 1 | 2014 | 411 | 0.100 |
Why?
|
Genetic Variation | 1 | 2012 | 245 | 0.090 |
Why?
|
Drug Interactions | 1 | 2010 | 79 | 0.090 |
Why?
|
Perfusion | 2 | 2008 | 73 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 2011 | 64 | 0.090 |
Why?
|
Nephrotic Syndrome | 1 | 2010 | 13 | 0.090 |
Why?
|
Kidney Tubules | 1 | 2010 | 26 | 0.090 |
Why?
|
Kidney Glomerulus | 1 | 2010 | 30 | 0.090 |
Why?
|
Genotype | 3 | 2017 | 734 | 0.090 |
Why?
|
Anuria | 1 | 2008 | 1 | 0.080 |
Why?
|
Age Factors | 3 | 2019 | 1194 | 0.080 |
Why?
|
Myoclonus | 1 | 2008 | 2 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 629 | 0.080 |
Why?
|
Phenotype | 3 | 2016 | 639 | 0.080 |
Why?
|
Extracorporeal Circulation | 1 | 2008 | 13 | 0.080 |
Why?
|
Organ Preservation | 1 | 2007 | 37 | 0.070 |
Why?
|
Nephrectomy | 2 | 2020 | 123 | 0.070 |
Why?
|
Comorbidity | 1 | 2008 | 569 | 0.070 |
Why?
|
Renal Dialysis | 1 | 2008 | 279 | 0.070 |
Why?
|
Treatment Outcome | 4 | 2016 | 3317 | 0.060 |
Why?
|
Hypertension | 1 | 2011 | 957 | 0.060 |
Why?
|
Chi-Square Distribution | 2 | 2016 | 298 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 757 | 0.060 |
Why?
|
Creatinine | 2 | 2016 | 195 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2016 | 687 | 0.050 |
Why?
|
Transplantation, Homologous | 1 | 2020 | 151 | 0.040 |
Why?
|
Resource Allocation | 1 | 2017 | 9 | 0.040 |
Why?
|
Survival Analysis | 1 | 2019 | 488 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 407 | 0.030 |
Why?
|
Infant | 1 | 2019 | 1061 | 0.030 |
Why?
|
Mutation | 1 | 2017 | 488 | 0.030 |
Why?
|
Reoperation | 1 | 2016 | 227 | 0.030 |
Why?
|
Preoperative Period | 1 | 2014 | 35 | 0.030 |
Why?
|
Child, Preschool | 1 | 2019 | 1269 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2015 | 146 | 0.030 |
Why?
|
Odds Ratio | 1 | 2016 | 474 | 0.030 |
Why?
|
Postoperative Period | 1 | 2014 | 97 | 0.030 |
Why?
|
Registries | 1 | 2016 | 298 | 0.030 |
Why?
|
Patient Selection | 1 | 2014 | 277 | 0.030 |
Why?
|
Heredity | 1 | 2012 | 13 | 0.030 |
Why?
|
Pedigree | 1 | 2012 | 140 | 0.030 |
Why?
|
Child | 1 | 2019 | 2441 | 0.030 |
Why?
|
Gene Frequency | 1 | 2012 | 220 | 0.030 |
Why?
|
Albuminuria | 1 | 2012 | 181 | 0.020 |
Why?
|
Brain Death | 1 | 2011 | 27 | 0.020 |
Why?
|
Immunosuppression | 1 | 2011 | 121 | 0.020 |
Why?
|
Adolescent | 1 | 2019 | 3526 | 0.020 |
Why?
|
Pancreas | 1 | 2011 | 104 | 0.020 |
Why?
|
European Continental Ancestry Group | 1 | 2015 | 1169 | 0.020 |
Why?
|
North Carolina | 1 | 2014 | 1516 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2012 | 900 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 507 | 0.020 |
Why?
|
Kidney | 1 | 2012 | 515 | 0.020 |
Why?
|
Death | 1 | 2008 | 50 | 0.020 |
Why?
|
Cryopreservation | 1 | 2007 | 57 | 0.020 |
Why?
|
Cohort Studies | 1 | 2011 | 1831 | 0.020 |
Why?
|
Risk Assessment | 1 | 2012 | 1435 | 0.020 |
Why?
|
Prospective Studies | 1 | 2011 | 2283 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2011 | 1428 | 0.010 |
Why?
|